کامیابی سے منعقد ہونے والی17 ویں سی آئی ایس ایم ای ایف کا مقصد دنیا بھر میں ایس ایم ایز کو فوائد اور مواقع فراہم کرنا تھا

گوانگژو، چین 20ستمبر 2021 /ژن ہوا-ایشیا نیٹ / –17ویں چائنا انٹرنیشنل  اسمال اینڈ میڈیم انٹرپرائز کا میلہ (سی ایس ایم ای ایف)16ستمبر تا 19ستمبر تک جنوبی چین کے صوبہ گوانگڈانگ کے دارالحکومت گوانگژو میں منعقد ہوا۔اس میلے نے 30سے زائد ممالک اور خطوں سے کمپنیوں کو شرکت کے لیے اپنی جانب متوجہ کیا۔یہ ایک زبردست پلیٹ فارم ہےاور ایس ایم ایز کو اندرون ملک اور بیرون ملک میں تعاون اور ترقی کا معیار بڑھانے کے نئے مواقع فراہم کرتاہے۔

روبوٹک ہاتھ ،خودکار گائیڈڈ گاڑیاں،مختلف مصنوعات نظروں کو دعوت دیتی ہے۔

تقریباً 1000کمپنیاں، جو یا تو مخصوص ٹیکنالوجی  میں سبقت رکھتی ہے،یا   ریفائنڈ مصنوعات اور تکنیک،نایاب اشیائ  یا سہولیات،یا ٹیکنالوجی اوریا پیداواری طریقے میں اختراعات،کرنے والی کمپنیوں نے سی آئی ایس ایم ای ایف میں حصہ لیا۔انھوں نے زیادہ تر بہترین تیاری اور مصنوعی ذہانت ،سازوسامان کی تیاری،الیکٹرانک معلومات ،بائیو میڈیسن،اور غذا اور زراعت جیسی صنعتی شعبوں پر توجہ دی ۔

شاندار نمائشوں کے علاوہ،کاروبار کےترقی کے مواقع اور سرگرمیوں کے تبادلے کی تمام اقسام بھی قابل توجہ ہیں۔سی آئی ایس ایم ای ایف نے سرگرمیوں کے ایک سلسلے کا بندوبست کیا جس کا ہدف نمائشی صنعتی شعبے ہیں،جن میں 12سپلائی اور ڈیما نڈ  کی ڈاکنگ سرگرمیاں،4موضوعاتی سرگرمیاں،3سرحد پار کاروباری معاہدے طے کرانے کی سرگرمیاں اور بیرون ملک نمائش کنندگان کے لیے 6تشہیری سرگرمیاں،اس امید کے ساتھ کہ نمائش کنندگان اور خریدار وں کو مزید جامع اور پر اثر سہولیات فراہم کیں جائے۔

گوانگژو کی کیمسون ٹریڈ کمپنی لمیٹیڈ پہلی بار سی آئی ایس ایم ای ایف میں حصہ لے رہی ہے۔کیمسون الیکٹرواسٹیٹک پاوٗڈر کوٹنگ ایریا میں مہارت رکھتی ہے،اور اپنے صارفین کو ذہین خودکار کوٹنگ اسکیم اور سہولیات فراہم کرتی ہے۔کیمسون کے ریسرچ اور ڈیولپمنٹ ڈائریکٹر شو گن کا کہناتھا ’’سی آئی ایس ایم ای ایف ہمارے جیسی خاص ٹیکنالوجی والی کمپنیوں کو ایک زبردست پلیٹ فارم مہیا کرتا ہے۔ایک طرف،ہمارے پاس موقع ہے کہ ہم اپنی مصنوعات اور برانڈ کی تشہیر کریں۔اور دوسر ی طرف، یہ ہمیں دوسرے شعبوں سے منفرد ٹیکنالوجی کے بارے میں سیکھنے میں مدد کرتاہے،جو پھر ہم یاد کر کے اپنے شعبے میں استعمال کرتے ہیں،اور صارفین کو بہتر سہولیات فراہم کرتے ہیں۔‘‘

رونمائی،لین دین،تبادلہ،تعاون۔سی آئی ایس ایم ای ایف ایک ایسے اہم پلیٹ فارم کے طور پر کام کرتا ہے جو دنیا بھر کے ایس ایم ایز کے لیے بنایاگیاہے۔یہ کمپنیوں کو سپلائر اور خریدار کے مابین تعاون کے لیے معلومات اور کاروباری ،اور تکنیکی تبادلے کے مواقع فراہم کرتاہے۔اسی دوران،یہ نمائش چین کے ابلاغ کے فروغ کی اور اندرون و بیرون ملک ایس ایم ایز کے مابین تعاون کی جانب زبردست راہ دکھاتاہے،اور کثیر الجہتی تجارت کا مشورہ دیتاہے۔

ایس ایم ایز کے لیے بین الاقوامی تعاون سمٹ،نمائش کے ساتھ مل کر،عالمی سطح پر ایس ایم ایز کے حصول کےقابل غورایک  منصوبے کاباقاعدہ اعلان کیا،جس کی مالیت 826.3بلین یوآن ہے۔سیمیناروں کا ایک سلسلہ رکھا گیا،جن میں ایس ایم ای کی حکمت عملیوں پر وزیروں کی سطح پر ایک راوٗ نڈ ٹیبل سیمینار تھا،جس میں ان تجربات کا تبادلہ کیاگیا کہ کس طرح ایس ایم ایز کی مشکلات کو بہتر طریقے سے حل کیاجائے۔

کئی نمائش کنندگان کے لیے،ایس ایم ایز کی یہ زبردست بین الاقوامی تقریب ان کو عالمی کاروباری سرگرمیوں کے ساتھ جڑنے کو مزید بڑھائیں گی اور باہمی فوائد اور عام ترقی حاصل کرنے میں مدد کرے گی۔گوانگڈانگ جیٹن روبوٹ اینڈ آٹومیشن کمپنی لمیٹیڈ نے اس میلے میں نئی خودکار گائیڈڈ  گاڑیاں پہلی بار متعارف کرائیں۔کمپنی کے ڈپٹی جنرل منیجر وانگ میکوئی کا خیال ہے کہ سی آئی ایس ایم ای ایف مصنوعات کی تشہیر کے لیے ایک اچھا موقع فراہم کرتاہے۔ان کا کہناتھا’’ہم چاہتے ہیں کہ مزیدلوگ ہماری مصنوعات کے بارے میں جانیں، اور یہ بہت اہم ہے۔‘‘

ذریعہ : سی آئی ایس ایم ای ایف

Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business Highlights and Second Quarter 2021 Financial Results

New Data Supporting Potential of ADG20 for Both the Treatment and Prevention of COVID-19 to be Presented at IDWeek 2021

Patient Population in Global EVADE Phase 2/3 Clinical Trial of ADG20 Expanded following IDMC Assessment

$355.8 Million IPO Completed to Fund Continued Advancement of Portfolio of Antibody-based Solutions for Infectious Diseases with Pandemic Potential

WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today reported updates on its lead COVID-19 antibody program, ADG20, as well as recent business highlights and second quarter 2021 financial results.

“Across the globe, COVID-19 continues to be a significant health crisis affecting nearly every age group. With the continued emergence of new variants, broadly neutralizing therapies that can be used for both the treatment and prevention of the disease are critical to address the current endemic as well as potential future outbreaks,” said Tillman Gerngross, Ph.D., co-founder and chief executive officer of Adagio. “Our team is working closely with our global CRO partners on the execution of our ongoing global clinical trials of ADG20, STAMP and EVADE, while also preparing for the anticipated worldwide commercialization of ADG20, if approved.

“ADG20 is a highly differentiated antibody that we are advancing through pivotal trials for both the treatment and prevention of COVID-19. We are pleased by the recent assessment of unblinded data by the IDMC for the EVADE trial, and their support of our plans to expand enrollment to include adolescents and pregnant or nursing women,” said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. “To date, we have generated a compelling data package for ADG20 that includes broad neutralization of the original SARS-CoV-2 virus and the known variants of concerns in in vitro models as well as a favorable pharmacokinetic and tolerability profile in our Phase 1 trial. Further, at this year’s IDWeek, we will release additional data from our Phase 1 trial as well as details regarding our dose selection process for treatment and prevention, which we believe further support the important role this novel antibody can play in combatting the ongoing pandemic.”

ADG20 COVID-19 Program Highlights

  • New ADG20 Data to be Presented in Multiple Posters during IDWeek: At the IDWeek 2021 Virtual Conference, Adagio plans to present additional data highlighting the potential for ADG20 to provide protection from COVID-19 for up to one year based on its extended half-life in humans combined with its broad and potent neutralizing ability demonstrated in laboratory testing. In addition, the data support the evaluation of a 300mg dose, delivered as a single intramuscular injection, in the ongoing Phase 2/3 STAMP (treatment) and EVADE (prevention) global clinical trials. The data will be presented in multiple posters, which will be available to registered attendees on the virtual platform throughout the duration of the conference, being held from September 29 – October 3, 2021. The presentations include:
    • 1086: A Whole-Body Quantitative System Pharmacology Physicologically-Based Pharmacokinetic (QSP/PBPK) Model that a priori Predicts Intramuscular (IM) Pharmacokinetics of ADG20: an Extended Half-life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)
    • 633: Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)
    • 1089: Use of a Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Prevention of Coronavirus Disease (COVID-19)
    • 1088: A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment of Coronavirus Disease (COVID-19)
  • Patient Population Expanded in EVADE following IDMC Data Assessment: The independent data monitoring committee (IDMC) for the EVADE Phase 2/3 trial of ADG20 for the prevention of COVID-19 recently provided a recommendation to expand Phase 3 trial enrollment to include adolescents 12 years and older and pregnant or nursing women, as well as a decrease in the protocol-specified, in-clinic post injection monitoring time. The IDMC’s recommendations were based on their review of unblinded safety and tolerability data through the Day 28 post-treatment visit from 200 participants enrolled in the Phase 2 lead-in portion of the trial.
  • Partnership with Biocon Biologics Expands the Reach of a Potent and Broadly Neutralizing COVID-19 Antibody Treatment to Patients in India and Select Emerging Markets: In the second quarter of 2021, Adagio partnered with Biocon Biologics Ltd. to combat the ongoing COVID-19 crisis in southern Asia. The partnership provides Biocon rights to manufacture and commercialize an antibody therapy based on ADG20 in India and additional select emerging markets based on the commercial manufacturing process developed for ADG20. As part of the agreement, Biocon will be granted access to data from Adagio’s Phase 2/3 clinical trials as well as its anticipated Emergency Use Authorization package and other regulatory submissions to support approval or emergency authorization in India and other select emerging markets.

Recent Business Highlights

  • David Hering, Global COVID-19 Vaccine Expert, Appointed as Chief Operating Officer: Adagio recently appointed David Hering as the company’s chief operating officer. Mr. Hering joins Adagio from Pfizer, where he most recently served as the global mRNA business lead, a business specifically created to manage global COVID-19 efforts as well as future vaccines utilizing mRNA technology, and led the launch of the first-ever COVID-19 vaccine in the United States. Prior to his most recent role at Pfizer, Mr. Hering was president, North America at Pfizer, where he led a 700-person organization across a portfolio of vaccine products for COVID-19 and meningococcal and pneumococcal diseases.
  • $355.8 Million Initial Public Offering (IPO) Successfully Completed: In August 2021, Adagio sold 20,930,000 shares of common stock, including the full exercise of the underwriters’ option to purchase an additional 2,730,000 shares of common stock at a public offering price of $17.00 per share. The gross proceeds of the offering, before underwriting discounts and commissions and other offering expenses payable by Adagio, were approximately $355.8 million.
  • Collaboration with Scripps: Adagio entered into an exclusive research agreement with The Scripps Research Institute to identify broadly protective vaccine candidates for the prevention of influenza and beta coronaviruses.
  • Board of Directors Expanded with Industry Leaders to Support Future Growth: Adagio recently announced appointments of three industry veterans and area experts to its board of directors:
    • Tom Heyman, former president of the Johnson & Johnson Development Corporation (JJDC);
    • Anand Shah, M.D., former deputy commissioner for medical and scientific affairs at the U.S. Food and Drug Administration (FDA); and
    • Michael S. Wyzga, president of MSW Consulting, Inc. and former CFO of Genzyme

Second Quarter 2021 Financial Results

  • As of June 30, 2021, Adagio had cash, cash equivalents and marketable securities of $392.5 million, which includes net proceeds from its Series C financing completed in April. Pro forma cash, cash equivalents and marketable securities as of June 30, 2021 is $719.6 million after giving effect to our initial public offering which closed on August 10, 2021.
  • Research & development expenses including in-process research and development for the second quarter of 2021 were $37.6 million.
  • Selling, general & administrative expenses for the second quarter of 2021 were $7.1 million.
  • Net Loss for the second quarter was $44.7 million, or $0.18 per share.

About ADG20
ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization against SARS-CoV-2 and additional clade 1 sarbecoviruses, by targeting a highly conserved epitope in the receptor binding domain. ADG20 displays potent neutralizing activity against the original SARS-CoV-2 strain as well as all known variants of concern. ADG20 has the potential to impact viral replication and subsequent disease through multiple mechanisms of action, including direct blocking of viral entry into the host cell (neutralization) and elimination of infected host cells through Fc-mediated innate immune effector activity. ADG20 is administered by a single intramuscular injection, and was engineered to have a long half-life, with a goal of providing both rapid and durable protection. Adagio is advancing ADG20 through multiple clinical trials on a global basis.

About Adagio Therapeutics

Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of our planned IND submissions, initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; our ability to obtain and maintain regulatory approvals for, our product candidates; our ability to identify patients with the diseases treated by our product candidates and to enroll these patients in our clinical trials; our manufacturing capabilities and strategy; and our ability to successfully commercialize our product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, those risks described under the heading “Risk Factors” in Adagio’s prospectus filed with the Securities and Exchange Commission (“SEC”) on August 6, 2021 and in Adagio’s future reports to be filed with the SEC, including Adagio’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts:

Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

ADAGIO THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(In thousands, except share and per share amounts)

June 30,
2021
December 31,
2020
Assets
Current assets:
Cash and cash equivalents(1) $ 392,509 $ 114,988
Prepaid expenses and other current assets 3,550 2,394
Total current assets 396,059 117,382
Deferred offering costs 1,933
Total assets $ 397,992 $ 117,382
Liabilities, Convertible Preferred Stock and Stockholders’ Deficit
Current liabilities:
Accounts payable $ 10,716 $ 8,153
Accrued expenses 27,181 4,919
Total current liabilities 37,897 13,072
Early-exercise liability 8 11
Total liabilities 37,905 13,083
Commitments and contingencies
Convertible preferred stock (Series A, B and C) $0.0001 par value; 16,944,484 shares authorized, issued and outstanding at June 30, 2021; 12,647,934 shares authorized, issued and outstanding at December 31, 2020; aggregate liquidation preference of $505,399 and $169,900 at June 30, 2021 and December 31, 2020, respectively 504,711 169,548
Stockholders’ deficit:
Common stock, $0.0001 par value; 150,000,000 shares authorized at June 30, 2021 and December 31, 2020; 5,599,240 shares issued and outstanding at June 30, 2021; 28,193,240 shares issued and 5,593,240 shares outstanding at December 31, 2020 1 1
Treasury stock, at cost; 0 shares and 22,600,000 shares at June 30, 2021 and December 31, 2020, respectively (85 )
Additional paid-in capital 4,067 154
Accumulated deficit (148,692 ) (65,319 )
Total stockholders’ deficit (144,624 ) (65,249 )
Total liabilities, convertible preferred stock and stockholders’ deficit $ 397,992 $ 117,382

(1)     Pro forma cash, cash equivalents and marketable securities as of June 30, 2021 is $719.6 million after giving effect to our issuance and sale of 20,930,000 shares of our common stock in our initial public offering at the price of $17.00 per share after deducting underwriting discounts, commissions and estimated offering costs which closed on August 10, 2021.

ADAGIO THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

(In thousands, except share and per share amounts)

Three Months
Ended
June 30,
Six Months
Ended
June 30,
Period from
June 3, 2020
(Inception) to
June 30,
2021 2021 2020 (3)
Operating expenses:
Research and development(1) $ 35,067 $ 69,204 $ 48
Acquired in-process research and development(2) 2,500 3,500
Selling, general and administrative 7,124 10,695 50
Total operating expenses 44,691 83,399 98
Loss from operations (44,691 ) (83,399 ) (98 )
Other income (expense):
Interest income 23 32
Other expense (5 ) (6 )
Total other income (expense), net 18 26
Net loss and comprehensive loss $ (44,673 ) $ (83,373 ) $ (98 )
Net loss per share attributable to common stockholders, basic and
diluted
$ (0.18 ) $ (0.66 ) $
Weighted-average common shares outstanding, basic and diluted 249,769 125,574 21,250,000

(1)   Includes related-party amounts of $247 for the three months ended June 30, 2021, $435 for the six months ended June 30, 2021 and $0 for the period from June 3, 2020 (inception) to June 30, 2020.
(2)   Includes related-party amounts of $2,500 for the three months ended June 30, 2021, $3,500 for the six months ended June 30, 2021 and $0 for the period from June 3, 2020 (inception) to June 30, 2020.
(3)   The results for the period from June 3, 2020 (inception) to June 30, 2020 are the same for the three and six months ended June 30, 2020.

FDA Clears First Technology to Distinguish between Bacterial and Viral Infections Using the Body’s Immune Response – The MeMed BV® Test and MeMed Key® Platform

FDA Clears First Technology to Distinguish between Bacterial and Viral Infections Using the Body’s Immune Response The MeMed BV® Test and MeMed Key® Platform

  • MeMed BV is a first-of-its kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes
  • MeMed Key is a pioneering platform that enables rapid and sensitive measurements of multiple proteins at the point-of-need
  • The MeMed technology suite enables better informed antibiotic treatment decisions, an essential tool in the fight against the global threat of resistant bacteria

HAIFA, Israel, Boston, MA; September 20th, 2021 – MeMed, a leader in the emerging field of advanced host-response technologies, today announces that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for use of the MeMed BV® test on the point-of-need platform MeMed Key® to help healthcare providers distinguish between bacterial and viral infections. The technology has been cleared for both children and adults.

Bacterial and viral infections are often clinically indistinguishable, leading to the prescription of antibiotics for the treatment of viral infections, for which they are ineffective. Antibiotic misuse drives the emergence of antimicrobial resistance (AMR), one of the biggest healthcare challenges of our time.
The novelty of MeMed’s technology is that it decodes the body’s immune response to infection, the ‘host response’, rather than focusing on detecting the presence of a microbe. This allows robust diagnosis when the infection site is inaccessible or unknown, even when the pathogen is undetectable using conventional tests, or when the cause of infection are emerging new pathogens. It enables better informed antibiotic treatment decisions, an essential tool in the fight against resistant bacteria.

“For those of us who care for acutely ill children, we have been waiting decades for accurate, rapid diagnostics to confidently guide the care of moderately ill children without a clear focus of infection or recognizable viral illness. This novel test offers promise to help differentiate those children with self-limited viral illness from those with possible bacterial infection, thereby supporting the judicious use of antibiotics,” said Rich Bachur, MD, Professor of Pediatrics and Emergency Medicine, Harvard Medical School, and Chief, Division of Emergency Medicine, Boston Children’s Hospital.

“It has been a decade long journey to reach this point from concept to impacting patient lives,” said Dr. Eran Eden, MeMed’s co-founder and CEO. “This FDA clearance is a breakthrough moment in the field of advanced host-response and could not have been achieved without the dedication of the MeMed team, our clinical partners in the US and around the globe, and the support of the US Department of Defense and EU Commission.”

Sergey Motov, MD, Professor of Emergency Medicine, Maimonides Medical Center, New York, said“Host-response technologies are a new frontier in the management of patients with infectious diseases, with great potential to improve patient outcomes. Every day, I see adults with a complicated medical history presenting to the emergency room with a suspected respiratory tract infection. A technology like MeMed BV can significantly aid in their management.”

“We are now using MeMed BV in my department routinely to aid in determining whether a child with fever has a bacterial or viral infection. For example, we recently had a complicated case of a young child with fever but without a clear source. MeMed BV helped in early identification of a severe bacterial infection, that would otherwise be masked by viral PCR detection, lead to a change in the course of treatment, and made a big difference in the patient’s outcome,” said Dr Adi Klein, Director of the Pediatric Division, Hillel Yaffe Medical Center and Head of the Israeli Clinical Pediatric Society. “Introducing MeMed’s technology has had a significant impact on our medical practice, enabling us to be better stewards of antibiotics and improving patient outcomes.”

FDA clearance was based on a multi-center blinded clinical validation study enrolling over 1,000 children and adults and addresses goals laid out in the US National Action Plan for Combating Antibiotic Resistant Bacteria. The test provides highly accurate results with Area Under the Curve of 90% and 97% (primary and secondary endpoints). MeMed has established its US base in Boston and is ramping up commercial activities to ensure broad availability of its products across the US.

About MeMed
Our mission is to translate the immune system’s complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society. To learn more about MeMed and our solutions, please visit http://www.me-med.com

About MeMed BV®
MeMed BV® is a first-of-its-kind immune-based protein signature test, developed and validated over the course of decade-long collaborations with leading academic and commercial partners. It provides physicians with an indispensable tool to help distinguish between bacterial and viral infections across multiple pathogens, even if the infection site is inaccessible or unknown. MeMed BV® measures and computationally integrates the levels of three immune system proteins: TRAIL, IP-10 and CRP. When run on the MeMed Key® platform, MeMed BV® provides a result within 15 minutes. MeMed BV® has been independently validated on thousands of patients and the results have been published in leading peer-reviewed journals (including PediatricsThe Lancet ID,  PLOS OneBMJ Peds and European Journal of Clinical Microbiology & Infectious Diseases). The MeMed BV® test has received a CE Mark in Europe and AMAR clearance from the Israeli Ministry of Health.

About MeMed Key®
MeMed Key® is a pioneering technology platform, enabling highly sensitive measurements of multiple proteins, within minutes, at the point of need. It opens the way to quantification of a vast array of human proteins in healthy and disease states, where and when it actually matters. The MeMed Key® development program has been partially funded by the US Department of Defense and the EU Commission. MeMed Key® has received a CE Mark in Europe and AMAR clearance from the Israeli Ministry of Health.

MeMed Contacts:
Adee Mor, VP Marketing, MeMed
pr@me-med.com
Kfir Emmer, CFO, MeMed
kfir.emmer@me-med.com

Media relations contact:
Consilium Strategic Communications MeMed@consilium-comms.com

Please click here to see the full release in Hebrew

17th CISMEF Successfully Held with Focus on Sharing Opportunities and Benefits for SMEs worldwide

GUANGZHOU, China, Sept. 20, 2021 /Xinhua-AsiaNet/– The 17th China International Small and Medium Enterprises Fair (CISMEF) is held from September 16th to 19th in Guangzhou, the capital of south China’s Guangdong province. The Fair has attracted enterprises from more than 30 countries and regions to participate. It provides a perfect platform and creates new opportunities for SMEs home and abroad to boost their cooperation and development.

With robotic arms, automatic guided vehicles, the various products are a feast for the eyes.

Approximately 1000 enterprises, which are leaders in either special technologies, refined products and techniques, unique goods or services, or innovation in technology or production modes, have exhibited in CISMEF. They mainly focus on the industrial fields of smart manufacturing and artificial intelligence, equipment manufacturing, electronic information, bio-medicine, and food and agricultural products.

Apart from many dazzling exhibits, all kinds of business promotion opportunities and exchange activities are also attractions. CISMEF have arranged a series of activities targeted at exhibiting industrial fields, including 12 supply and demand docking activities, 4 thematic activities, 3 cross-border business matchmaking activities and 6 promotion activities for exhibitors abroad, in the hope of providing exhibitors and purchasers with more accurate and effective services.

It will be the first time for Kimsun Trade Co.LTD from Guangzhou participates in the CISMEF. Kimsun specializes in the electrostatic powder coating area, providing their customers with intelligent automatic coating schemes and services. Shu Gan, the Research and Development Director of Kimsun, indicated, “CISMEF provides an excellent platform for enterprises of special technologies like us. On the one hand, we have chances to promote our products and brands. On the other hand, it enables us to learn more about unique technologies from other areas, then absorbs and applies them into our area, offering customers better solutions.”

Display, transaction, exchange, cooperation. CISMEF has been working as an essential platform tailored for SMEs around the world. It provides information and business opportunities for enterprises to look for corporations between suppliers and buyers, and technical exchanges. Meanwhile, the Fair also strongly signals China’s promotion of communication and corporation between SMEs home and abroad, and proposes multilateral trade.

The International Cooperation Summit for SMEs, coupling with the fair, officially announced a considerable procurement plan for SMEs globally, valued at 826.3 billion yuan. A series of seminars have been arranged, including a ministerial-level roundtable centering on SME policies, to share experiences on how to effectively solve SMEs’ difficulties.

For many exhibitors, this superb international event of SMEs will accelerate their integration into global value chains and achieve mutual benefit and common prosperity. Guangdong Jaten Robot&Automation Co. Ltd debuts their new product of Automated Guided Vehicles in the Fair. Wang Meikui, the Deputy General Manager of the company, thinks that CISMEF provides a good chance for them to promote the product. “We would like to let more people get to know our product, and it’s very important,” she said.

Source: CISMEF

Chairman Senate lauds Punjab Govt’s steps to promote inter-provincial harmony

Chairman Senate Sadiq Sanjrani and Senator Abdul Qadir called on the Punjab Chief Minister Sardar Usman Buzdar in Lahore on Monday.

Speaking on this occasion, Chief Minister Usman Buzdar said Punjab government has taken exemplary steps to promote inter-provincial harmony and progress and prosperity of Balochistan is the development of the country.

Chairman Senate Sadiq Sanjrani appreciated the steps taken by Punjab government to promote inter-provincial harmony.

Source: Radio Pakistan

Covid-19: 40 more deaths, 2167 positive cases reported in country

Forty more deaths due to Coronavirus infection and 2,167 positive cases have been reported in the country.

According to the National Command and Operation Centre statistics, 51,348 tests were conducted yesterday while positivity ratio remained 4.22 percent.

Death toll due to the pandemic has now reached 27, 246.

Source: Radio Pakistan

FIA Jails CEO Elahi Group of Companies and Former Private Bank Officers for ‘Embezzlement’

The Federal Investigation Agency (FIA) has jailed Danish Elahi, Chief Executive Officer (CEO) Elahi Group of Companies, along with a few former employees of BankIslami Pakistan Limited, as a first information report (FIR) was registered against them for alleged embezzlement, involving irregularities and suspicious transactions discovered in their accounts.

Reports suggest that the evidence of misappropriation of financial assets against the accused has already been proven, and their remand was approved by a magistrate on a later date.

The Elahi Group is also an alleged defaulter of the bank, owing well over Rs. 1.4 billion in debt and related payments. In this regard, sources said, FIA was conducting a separate inquiry against defaulters and it was subject to further investigation upon retrieval of more evidence in the near future.

The Elahi Group of Companies has been involved in the supply chain business segment for procurement of raw materials for different manufacturing purposes, like production of transformers, inventory management, and storage and logistics of huge volume.

With the underlined embezzlement case likely to add up to the hardships in the company’s mounting struggles, many will wonder how the leadership behind the Elahi Group managed to fool regulators for so long with unverified holdings and off-the-books accounting practices.

Source: Pro Pakistani

Fitch Predicts Pakistan’s Economic Recovery to Continue in FY2021-22

Fitch Solutions maintained its forecast for the Pakistani economy to record real GDP growth of 4.2 percent in the fiscal year 2021-22, up from 3.9 percent in the fiscal year 2020-21.

“We note that improving vaccination rates will buoy private consumption growth while supportive monetary and fiscal conditions will serve as tailwinds for gross fixed capital formation. Net exports will contribute negatively to headline growth as import growth is set to outpace export growth”, said Fitch Solutions in its latest report on Pakistan.

It further stated that the forecast accounts for the occasional tightening of COVID-19 restriction measures due to the still-elevated number of domestic COVID-19 cases. This comes as Pakistan grapples with its fourth wave of COVID-19 outbreaks. Nevertheless, with the government likely to continue with its “smart-lockdown” strategy instead of imposing a nationwide lockdown, Fitch solutions do not expect Pakistan’s growth trajectory to be severely curtailed.

“Additionally, the pickup in the vaccination rate in recent months will likely reduce the possibility of extended lockdowns in the future. We also expect the economy to be buoyed by accommodative monetary and fiscal stances (public spending). A more assured economic outlook will bode well for consumption and investments, bolstering economic growth,” it added.

In FY21, the Pakistan economy proved resilient towards the COVID-19 pandemic, registering real GDP growth of 3.9 percent. Growth was driven primarily by private consumption, contributing 6.2pp to headline figures due to base effects and strong remittance flows, it added,

Gross fixed capital formation (GFCF) contributed 0.8pp to headline figures supported by accommodative monetary policy. Meanwhile, government consumption contribution to GDP fell compared to 2020, adding 0.5pp to overall growth, compared with 0.8pp the previous year due to reduced financial support to the economy.

Finally, net exports subtracted 2.7pp from the headline growth figure, dragged by a rebound in imports given stronger domestic demand and higher oil prices.

“We have revised our forecast for private consumption to grow by 3.6% in FY22 compared to 3.4 percent previously. While this still represents a slowdown from the 7.4 percent in FY21 due to waning base effects, improving vaccination rates will buoy consumer sentiment, facilitating recovery in consumer spending. As of September 12, 22.8 percent of the population has received at least one dose of the vaccine with 9.6 percent of the population is fully vaccinated. Although still far from achieving herd immunity (approximately at least 70 percent of the population fully vaccinated), these figures represent about a seven-fold increase since our last update in June,” said the report.

“This comes as the government is looking to vaccinate about 70 million people (31 percent of the population) by the end of 2021. Indeed, the country’s consumer confidence rose in July, coming in at 44.1, its highest reading since September 2019 (pre-pandemic levels). As a sign of recovering demand, purchases of major items like passenger vehicle sales have surpassed pre-pandemic levels. Additionally, our expectation for still strong remittance growth amid a stronger economic growth outlook in the Gulf Cooperation Council (GCC) economies and the European Union, will also support private consumption,” it added.

Fitch Solution has also revised up its forecast for GFCF growth to 8.0 percent in FY22 from 7.2 percent previously. GFCF will be driven by improving domestic and external demand outlooks alongside supportive monetary and fiscal conditions.

The country’s business confidence survey by the State Bank Of Pakistan (SBP) recorded its highest ever levels in June (latest data available) since its inception, reflecting optimism surrounding the business outlook of Pakistan. Accommodative monetary policy, coupled with disbursements from the SBP’s Temporary Economic Refinance Facility (TERF) will further serve as tailwinds for capacity enhancing investments.

According to the SBP estimates, TERF loan disbursements are expected to increase by 67 percent this fiscal year. The TERF is a concessionary refinance facility that aims to stimulate capital investment, providing a maximum loan amount of Rs5bn per project at a cost of 4 percent per annum.

Increased development spending by the government will be another catalyst for growth in this component. According to Pakistan’s FY22 fiscal budget, allocations to the Public Sector Development Programme surged by 61.3 percent compared with the budgeted amount in the previous fiscal year, coming in at Rs. 2.1 trillion, said Fitch Solutions.

These include infrastructure projects such as the construction of the Diamer-Bhasha Dam, the Hyderabad-Sukkur motorway, and the upgrade of Pakistan Railways’ existing Main Line-1, among others.

Meanwhile, Fitch Solutions revised up its forecast for government consumption growth to register at 4.3 percent in FY22 from their previous forecast of 3.5 percent. This is broadly similar to the growth rate of 4.1 percent witnessed in FY21. Given the continued economic uncertainty from the pandemic, they expect pandemic-related spending to remain broadly similar to ensure the economic recovery does not fall off track.

According to the World Bank, the poverty ratio in Pakistan (using the lower-middle-income poverty line of USD3.2 per person per day) will remain similar in FY22 compared to FY21 (39.2 percent vs. 39.3 percent respectively). Additionally, government consumption will also be boosted by subsidies to the power sector to ameliorate the country’s circular debt. In short, circular debt refers to a payment deficit at the Central Power Purchasing Agency (CPPA) due to a shortfall in receivables by distribution companies.

This prevents the CPPA from meeting payment obligations to power producers who, in turn, default on payments towards fuel suppliers.

Lastly, Fitch now expects net exports to subtract 1.0pp from headline growth, revised from -0.4pp previously. This comes as they expect imports to rebound more strongly than exports. Imports will be supported by increased demand for vaccines, with the government recently committing USD1.1 billion to procure COVID-19 vaccines.

Additionally, the improving economic outlook will likely see a rebound in consumer spending and increased demand for capital goods.

Finally, with petroleum products accounting for approximately 18.0 percent of total imports value in FY21, elevated fuel prices will further increase Pakistan’s imports bill. Fitch’s Oil and Gas team forecasts Brent crude oil prices to average USD72.00 per barrel (/bbl) in 2021 and USD69.00/bbl in 2022 from USD43.20/bbl in 2020. Hence, they pencil in 8.0% growth in imports for FY22, a revision upwards from its previous expectation of 5.0 percent growth.

Meanwhile, Fitch continues to expect Pakistan’s export growth to come in at 6.0 percent. Export growth will be bolstered by robust external demand amid recoveries among Pakistan trading partners such as the US, China, and the United Kingdom. As these economies continue to normalize activity with the gradual easing of lockdown measures due to higher vaccination rates, the improvement in consumer sentiment in these markets will lead to stronger order flows.

Nevertheless, supply-chain disruptions due to the pandemic and rising shipping costs will slightly crimp the country’s export outlook amid disruptions in production schedules.

Risk To Outlook

The risk to the growth outlook is weighted to the downside. On the domestic front, given the more virulent delta strain in the community, amid a still low percentage of the population that are fully vaccinated, a strong resurgence in COVID-19 infections could weigh heavily on growth.

On the external front, heightened security threats posed by radical groups such as the Pakistan Taliban Group could lead to social instability and the destruction of infrastructure. This might weigh on the country’s gross fixed capital outlook and exporting capabilities as businesses become hesitant to invest in capacity-building infrastructure.

Source: Pro Pakistani